{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T17:19:39Z","timestamp":1761844779003},"reference-count":17,"publisher":"Maad Rayan Publishing Company","issue":"3","content-domain":{"domain":["nephropathol.com"],"crossmark-restriction":true},"short-container-title":["J Nephropathol"],"DOI":"10.15171\/jnp.2017.23","type":"journal-article","created":{"date-parts":[[2017,9,21]],"date-time":"2017-09-21T14:48:31Z","timestamp":1506005311000},"page":"134-137","update-policy":"http:\/\/dx.doi.org\/10.15171\/crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Self-limited membranous nephropathy after intravitreal bevacizumab therapy for age-related macular degeneration"],"prefix":"10.34172","volume":"6","author":[{"given":"Gebran","family":"Khneizer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmad","family":"Al-Taee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bahar","family":"Bastani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"20123","published-online":{"date-parts":[[2017,2,5]]},"reference":[{"key":"R1","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1210\/er.2003-0027","article-title":"Vascular endothelial growth factor: basic science and clinical progress","volume":"25","author":"Ferrara N","year":"2004","journal-title":"Endocr Rev"},{"key":"R2","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1053\/j.ajkd.2006.11.039","article-title":"Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis","volume":"49","author":"Zhu X","year":"2007","journal-title":"Am J Kidney Dis"},{"key":"R3","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/j.ophtha.2007.01.017","article-title":"Pharmacokinetics of intravitreal bevacizumab (Avastin)","volume":"114","author":"Bakri SJ","year":"2007","journal-title":"Ophthalmology"},{"key":"R4","doi-asserted-by":"publisher","DOI":"10.1089\/jop.2013.0009"},{"key":"R5","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s00417-007-0660-z","article-title":"Twelve-month safety of intravitreal injections of bevacizumab (Avastin): results of the Pan-American Collaborative Retina Study Group (PACORES)","volume":"246","author":"Wu L","year":"2008","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R6","doi-asserted-by":"publisher","DOI":"10.1007\/s00417-007-0660-z"},{"key":"R7","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1172\/JCI17423","article-title":"Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases","volume":"111","author":"Eremina V","year":"2003","journal-title":"J Clin Invest"},{"key":"R8","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1681\/ASN.V75661","article-title":"Expression of vascular permeability factor (VPF\/VEGF) is altered in many glomerular diseases","volume":"7","author":"Shulman K","year":"1996","journal-title":"J Am Soc Nephrol"},{"key":"R9","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2010020167"},{"key":"R10","doi-asserted-by":"publisher","DOI":"10.1159\/000321630"},{"key":"R11","doi-asserted-by":"publisher","DOI":"10.3129\/i10-027"},{"key":"R12","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1097\/IAE.0b013e3182278ab4","article-title":"A systematic review of the adverse events of intravitreal anti-vascular endothelial growth factor injections","volume":"31","author":"van der Reis MI","year":"2011","journal-title":"Retina"},{"key":"R13","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.survophthal.2009.02.004","article-title":"Bevacizumab (Avastin) for the treatment of ocular disease","volume":"54","author":"Gunther JB","year":"2009","journal-title":"Surv Ophthalmol"},{"key":"R14","first-page":"1226 e1","article-title":"Systemic adverse events after bevacizumab","volume":"116","author":"Roth DB","year":"2009","journal-title":"Ophthalmology"},{"key":"R15","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0b013e3182278ab4"},{"key":"R16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcjo.2011.12.024"},{"key":"R17","doi-asserted-by":"publisher","DOI":"10.3265\/Nefrologia.pre2014.Mar.12388"}],"container-title":["Journal of Nephropathology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/nephropathol.com\/pdf\/jnp-6-134.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,3]],"date-time":"2022-08-03T04:36:31Z","timestamp":1659501391000},"score":1,"resource":{"primary":{"URL":"http:\/\/nephropathol.com\/Abstract\/JNP_20170220204700"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2,5]]},"references-count":17,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2017,7]]}},"URL":"https:\/\/doi.org\/10.15171\/jnp.2017.23","relation":{},"ISSN":["2251-8363","2251-8819"],"issn-type":[{"value":"2251-8363","type":"print"},{"value":"2251-8819","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,2,5]]}}}